Quick Answer
Design Therapeutics, Inc. reported Net Income Loss of -$69.79 million for the year ending 2025.
- Design Therapeutics, Inc. showed a decrease of -40.7% in Net Income Loss from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$663.0 thousand | Q2 2020: -$1.44 million | Q3 2020: -$2.32 million | Q1 2021: -$5.51 million | Q2 2021: -$7.64 million | Q3 2021: -$11.32 million | Q1 2022: -$13.27 million | Q2 2022: -$15.00 million | Q3 2022: -$17.70 million | Q1 2023: -$19.29 million | Q2 2023: -$19.94 million | Q3 2023: -$15.79 million | Q1 2024: -$11.11 million | Q2 2024: -$11.79 million | Q3 2024: -$13.04 million | Q1 2025: -$17.72 million | Q2 2025: -$19.08 million | Q3 2025: -$17.00 million.
- Over the full 6 years of available data (2020 to 2025), Design Therapeutics, Inc.'s Net Income Loss has declined by 742.9%.
- Historical annual values: Fiscal year 2025: -$69.79 million | Fiscal year 2024: -$49.59 million | Fiscal year 2023: -$66.86 million | Fiscal year 2022: -$63.31 million | Fiscal year 2021: -$35.53 million | Fiscal year 2020: -$8.28 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: